Lercanidipino Viatris (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in the smooth muscle of arteries. This inhibition reduces calcium entry into the cells, causing the muscle to relax, which widens the blood vessels (vasodilation). The resulting decrease in peripheral vascular resistance leads to lower systolic and diastolic blood pressure.

The exact dose of lercanidipine is determined by the prescribing clinician based on the patient’s blood‑pressure readings, age, renal and hepatic function, and concomitant medications. The prescriber will select the appropriate strength and titrate as needed to achieve optimal control.

Safety data for lercanidipine in pregnancy and lactation are limited, and the product is generally not recommended unless the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class, which primarily causes arterial vasodilation. Compared with ACE inhibitors or ARBs, it may produce fewer cough or angio‑edema issues but can be associated with peripheral edema. Choice of therapy depends on patient comorbidities, tolerability, and physician preference.

Lercanidipino Viatris should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water and do not crush or chew it unless instructed otherwise.

Serious adverse events, though rare, include severe hypotension, angio‑edema, myocardial infarction, hepatic dysfunction, and anaphylactic reactions. Patients should seek immediate medical attention if they experience sudden dizziness, swelling of the face or throat, chest pain, or signs of liver injury.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation, and in individuals with severe hypotension (blood pressure markedly below normal). Caution is also advised for patients with significant hepatic impairment or those taking strong CYP3A4 inhibitors.